

12-12-01



# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.

11268A

Total Pages in this Submission

## TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application  
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

**A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME**

and invented by:

Douglas J. Hilton, Tracy Willson, Timothy Gainsford, Warren S. Alexander, Donald Metcalf, Ashley Ng and Nicos A. Nicola

If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:

Continuation  Divisional  Continuation-in-part (CIP) of prior application No.: 09/043,816

Which is a:

Continuation  Divisional  Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Which is a:

Continuation  Divisional  Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_

Enclosed are:

### Application Elements

1.  Filing fee as calculated and transmitted as described below
2.  Specification having 50 pages and including the following:
  - a.  Descriptive Title of the Invention
  - b.  Cross References to Related Applications (*if applicable*)
  - c.  Statement Regarding Federally-sponsored Research/Development (*if applicable*)
  - d.  Reference to Microfiche Appendix (*if applicable*)
  - e.  Background of the Invention
  - f.  Brief Summary of the Invention
  - g.  Brief Description of the Drawings (*if drawings filed*)
  - h.  Detailed Description
  - i.  Claim(s) as Classified Below
  - j.  Abstract of the Disclosure

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.

11268A

Total Pages in this Submission

**Application Elements (Continued)**

3.  Drawing(s) (*when necessary as prescribed by 35 USC 113*)  
a.  Formal Number of Sheets 20 (Figs 1-9)  
b.  Informal Number of Sheets \_\_\_\_\_
4.  Oath or Declaration  
a.  Newly executed (*original or copy*)  Unexecuted  
b.  Copy from a prior application (37 CFR 1.63(d)) (*for continuation/divisional application only*)  
c.  With Power of Attorney  Without Power of Attorney  
d.  DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application,  
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5.  Incorporation By Reference (*usable if Box 4b is checked*)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under  
Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby  
incorporated by reference therein.
6.  Computer Program in Microfiche (*Appendix*)
7.  Nucleotide and/or Amino Acid Sequence Submission (*if applicable, all must be included*)  
a.  Paper Copy  
b.  Computer Readable Copy (*identical to computer copy*)  
c.  Statement Verifying Identical Paper and Computer Readable Copy

**Accompanying Application Parts**

8.  Assignment Papers (*cover sheet & document(s)*)
9.  37 CFR 3.73(B) Statement (*when there is an assignee*)
10.  English Translation Document (*if applicable*)
11.  Information Disclosure Statement/PTO-1449  Copies of IDS Citations
12.  Preliminary Amendment
13.  Acknowledgment postcard
14.  Certificate of Mailing

First Class  Express Mail (*Specify Label No.*): EV052766490US

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.

11268A

Total Pages in this Submission

**Accompanying Application Parts (Continued)**

15.  Certified Copy of Priority Document(s) (*if foreign priority is claimed*)

16.  Additional Enclosures (*please identify below*):

**Request to Use Computer Readable Form of Sequence Listing From Another Application Under 37 C.F.R. 1.821(e) and Statement Under 37 C.F.R. 1.821(f)**

**Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)**

17.  Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

**Warning**

***An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.***

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.

11268A

Total Pages in this Submission

**Fee Calculation and Transmittal**

**CLAIMS AS FILED**

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	96	- 20 =	76	x \$18.00	\$1,368.00
Indep. Claims	1	- 3 =	0	x \$84.00	\$0.00
Multiple Dependent Claims (check if applicable)	<input checked="" type="checkbox"/>				\$280.00
Please calculate claims as amended by Preliminary Amendment					BASIC FEE \$740.00
OTHER FEE (specify purpose)					\$0.00
					<b>TOTAL FILING FEE \$2,388.00</b>

- A check in the amount of \$2,388.00 to cover the filing fee is enclosed.
- The Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed.
  - Charge the amount of \_\_\_\_\_ as filing fee.
  - Credit any overpayment.
  - Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
  - Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).



Signature

Dated: December 7, 2001

CC:

Leopold Presser  
 Registration No. 19,827  
 Scully, Scott, Murphy & Presser  
 400 Garden City Plaza  
 Garden City, New York 11530  
 (516) 742-4343

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)**

Applicant(s): Douglas J. Hilton, et al.


Docket No.

11268a

Serial No.  
To Be AssignedFiling Date  
HerewithExaminer  
UnassignedGroup Art Unit  
Unassigned

Invention: A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME

I hereby certify that the following correspondence:

**New Patent Application (Divisional)***(Identify type of correspondence)*is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under  
37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 onDecember 7, 2001*(Date)***Janet Grossman***(Typed or Printed Name of Person Mailing Correspondence)*  
*(Signature of Person Mailing Correspondence)***EV052766490US***("Express Mail" Mailing Label Number)*

Note: Each paper must have its own certificate of mailing.

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)**

Applicant(s): Douglas J. Hilton, et al.

Docket No.

11268a

Serial No.  
**To Be Assigned**Filing Date  
**Herewith**Examiner  
**Unassigned**Group Art Unit  
**Unassigned**

Invention: A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME

I hereby certify that the following correspondence:

**New Patent Application (Divisional)***(Identify type of correspondence)*

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under

37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on

**December 7, 2001***(Date)***Janet Grossman***(Typed or Printed Name of Person Mailing Correspondence)*  
*Janet Grossman**(Signature of Person Mailing Correspondence)***EV052766490US***("Express Mail" Mailing Label Number)*

Note: Each paper must have its own certificate of mailing.

PATENTS

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant(s):** Douglas J. Hilton, et al.      **Examiner:** Unassigned  
**Serial No.:** To Be Assigned      **Art Unit:** Unassigned  
**Filed:** Herewith      **Docket:** 11268a  
**For:** A NOVEL HAEMOPOIETIN RECEPTOR  
AND GENETIC SEQUENCES ENCODING  
SAME      **Dated:** December 7, 2001

Assistant Commissioner for Patents  
United States Patent and Trademark Office  
Washington, D.C. 20231

**STATEMENT UNDER 37 C.F.R. §1.821(f)**

Sir:

I hereby state that the content of the paper copy of the Sequence Listing submitted in accordance with 37 C.F.R. §§1.821(c) and (e), respectively, is identical to that filed on November 21, 2001 in Application Serial Number 09/043,816.

Respectfully submitted,



Frank S. DiGiglio  
Registration No. 31,346

SCULLY, SCOTT, MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343  
FSD/XZ:ab


**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

"Express Mail" Mailing Label Number: EV052766490US

Date of Deposit: December 7, 2001

I hereby certify that this Correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents and Trademarks, Washington, DC 20231.

Dated: December 7, 2001



Janet Grossman  
Janet Grossman

PATENTS

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Applicant(s):</b>	Douglas J. Hilton, et al.	<b>Examiner:</b>	Unassigned
<b>Serial No.:</b>	To Be Assigned	<b>Art Unit:</b>	Unassigned
<b>Filed:</b>	Herewith	<b>Docket:</b>	11268a
<b>For:</b>	A NOVEL HAEMOPOIETIN RECEPTOR AND GENETIC SEQUENCES ENCODING SAME	<b>Dated:</b>	December 7, 2001

Assistant Commissioner for Patents  
United States Patent and Trademark Office  
Washington, D.C. 20231

**REQUEST TO USE COMPUTER READABLE FORM OF SEQUENCE LISTING FROM  
ANOTHER APPLICATION UNDER 37 C.F.R. §1.821(e)**

Sir:

The computer readable form of the Sequence Listing in the above-identified patent application is identical to that filed on November 21, 2001 in Application Serial Number: 09/043,816. In accordance with 37 C.F.R. §1.821(e), Applicants respectfully request that the computer readable form filed in Application Number 09/043,816 be used as the computer readable form in the above-identified application.

---

**CERTIFICATE OF MAILING BY "EXPRESS MAIL"**

"Express Mail" Mailing Label Number: EV052766490US

Date of Deposit: December 7, 2001

I hereby certify that this Correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents and Trademarks, Washington, DC 20231.

Dated: December 7, 2001

*Janet Grossman*  
Janet Grossman

It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form used in the above-identified application. A paper copy of the Sequence Listing is included in the original filed specification of the above-identified application.

Respectfully submitted,



SCULLY, SCOTT, MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343  
FSD/XZ:ab

Frank S. DiGiglio  
Registration No. 31,346